Guy Cipriani MBA, BS
Mr. Cipriani is an executive with over 15 years experience in the pharmaceutical and biotech industry. Most recently, he served as VP of Business Development at Cascadian Therapeutics since 2012. Prior to that role, Mr. Cipriani served as VP of Business Development at Cardiome Pharma Corp. At Cardiome, he led the negotiating team to secure a US $800 million global development and co-commercialization licensing deal with Merck & Company around the company's lead cadiovascular product for atrial fibrillation. Prior to Cardiome, Mr. Cipriani served as Sr. Director of Business Development for TransForm Pharmaceuticals, Inc., and he also worked for five years in Corporate Business Development for Eli Lilly and Company.
Mr. Cipriani's extensive background includes corporate and business development, strategic planning, alliance management, and product development. He has successfully completed over twenty licensing deals of various types, including commercialization agreements, development agreements, discovery collaborations, distribution agreements, etc. across multiple therapeutic areas including cardiovascular, infectious disease, oncology, and CNS. Mr. Cipriani holds a B.S.E.E., High Honors from Rochester Institute of Technology and an MBA from the Kellogg Graduate School of Management at Northwestern University.